Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) A compound of formula I

wherein

X is $=CR^0$ - or =N-;

- each of R⁰, R¹, R², R³ and R⁴ independently is hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkyl-C₁-C₈alkyl; hydroxyC₁-C₈alkyl; C₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkoxyC₁-C₈alkyl; arylC₁-C₈alkyl which optionally may be substituted on the ring by hydroxy, C₁-C₈alkoxy, carboxy or C₁-C₈alkoxycarbonyl;
- or R³ and R⁴ form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;
- or each of R¹, R² and R³, independently, is halogen; halo-C₁-C₀alkyl; C₁-C₀alkoxy; halo-C₁-C₀alkoxy; hydroxyC₁-C₀alkoxy; C₁-C₀alkoxyC₁-C₀alkoxy; aryl; arylC₁-C₀alkoxy; heteroaryl; heteroaryl-C₁-C₄alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; C₂-C₀alkoxycarbonyl; C₂-C₀alkylcarbonyl; -N(C₁-C₀alkyl)C(O) C₁-C₀alkyl; -N(R¹⁰)R¹¹; -CON(R¹⁰)R¹¹; -SO₂N(R¹⁰)R¹¹; or -C₁-C₄-alkylene-SO₂N(R¹⁰)R¹¹; wherein each of R¹⁰ and R¹¹ independently is hydrogen; hydroxy; C₁-C₀alkyl; C₂-C₀alkenyl; C₃-C₀cycloalkyl; C₃-C₀cycloalkyl-C₁-C₀alkyl; C₁-C₀alkoxyC₁-C₀alkyl; hydroxyC₁-C₀alkoxyC₁-C₀alkyl; hydroxyC₁-C₀alkyl; (C₁-C₀alkyl)-carbonyl; arylC₁-C₀alkyl which optionally may be substituted on the ring by hydroxy, C₁-C₀alkoxy, carboxy or C₂-C₀alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;
- or R¹ and R² form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O and S; or
- each of R^5 and R^6 independently is hydrogen; halogen; cyano; C_1 - C_8 alkyl; halo- C_1 - C_8 alkyl; C_2 - C_8 alkenyl; C_2 - C_8 alkynyl; C_3 - C_8 cycloalkyl; C_3 - C_8 cycloalkyl C_1 - C_8 alkyl; C_5 - C_{10} aryl C_1 - C_8 alkyl; each of R^7 . R^8 and R^9 is independently hydrogen; hydroxy; C_1 - C_8 alkyl; C_2 - C_8 alkenyl;

halo- C_1 - C_8 alkyl; C_1 - C_8 alkoxy; C_3 - C_8 cycloalkyl; C_3 - C_8 cycloalkyl C_1 - C_8 alkyl; aryl C_1 - C_8 alkyl; -Y- R^{12} wherein Y is a direct bond or O and R^{12} is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; $(C_1$ - C_8 alkoxy)-carbonyl; -N(C_{1-8} alkyl)-CO-NR 10 R 11 ; -CONR 10 R 11 ; -N(R^{10})(R^{11}); -SO $_2$ N(R^{10})R 11 ; R^7 and R^8 or R^8 and R^9 , respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.

in free form or salt form.

Claim 2. (Original) A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II

wherein R¹, R², R³, R⁴, R⁵, R⁶ and X are as defined in claim 1, and Y is a leaving group; with a compound of formula III

$$R^7$$
 R^8
 H_2N
 R^9
(III)

wherein R7, R8 and R9 are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

Claim 3. (Original) A compound according to claim 1 in free form or in pharmaceutically acceptable salt form, for use as a pharmaceutical.

Claim 4. (Original) A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.

Claims 5-6. (Canceled)

Claim 7. (Original) A combination which comprises (a) a therapeutically effective amount of a ZAP-70, FAK and/or Syk inhibitor and (b) a second drug substance.

Claim 8. (Original) A method for treating or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.

Claim 9. (Original) A method for treating or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a ZAP-70, FAK and/or Syk inhibitor in combination with a second drug substance.